SEC Form 4 · accession 0001562180-16-003843
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Anderson
Officer — See Remarks
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 15, 2016 | M | 1,900 | $8.92 | A | 1,900 | D | |
| Common Stock | Dec 15, 2016 | F | 346 | $48.99 | D | 1,554 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.92 | Dec 15, 2016 | M | 1,900 | D | — | May 21, 2024 | Common Stock | 1,900 | 165,138 | D |
Explanation of responses
- F1The disposition reported on this Form 4 were effected pursuant to a stock swap using existing employee stock purchase (espp) shares.
- F2The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in full on May 5, 2018, subject to continued service through such date.
Remarks
Chief Commercial Strategy Officer